Camp4 has attracted capital from investors such as Kraft Group to continue development of its drug discovery platform based on work at MIT and Harvard Medical School.
US-based drug discovery company Camp4 Therapeutics has raised $30m in a series A round from a consortium including conglomerate Kraft Group.
The round was led by Andreessen Horowitz and also featured Polaris Partners, which previously provided an undisclosed amount of seed funding.
Founded in 2016, Camp4 has built a platform that uses cellular and genetic insights to better understand how genes are controlled by signaling pathways in specific disease states.
The company builds on initial work undertaken by founders Richard…
